Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Market Cap	8.37B
Revenue (ttm)	54.70M +698.0%
Net Income	-439.90M
EPS	-1.52
Shares Out	325.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,536,380
Open	24.74
Previous Close	24.94
Day's Range	24.38 - 26.48
52-Week Range	23.34 - 206.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2026

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 354
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2659

Financial Performance

In 2025, HKG:2659's revenue was 49.16 million, an increase of 697.99% compared to the previous year's 6.16 million. Losses were -395.30 million, 8.47% more than in 2024.

Financial numbers in CNY